Assenagon Asset Management S.A. Has $2.53 Million Stock Holdings in CytomX Therapeutics, Inc. $CTMX

Assenagon Asset Management S.A. decreased its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 18.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 592,696 shares of the biotechnology company’s stock after selling 137,271 shares during the period. Assenagon Asset Management S.A.’s holdings in CytomX Therapeutics were worth $2,525,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Orbimed Advisors LLC acquired a new stake in CytomX Therapeutics during the second quarter worth approximately $19,208,000. Commodore Capital LP bought a new stake in shares of CytomX Therapeutics during the second quarter worth approximately $17,462,000. Perceptive Advisors LLC acquired a new position in shares of CytomX Therapeutics in the second quarter valued at approximately $15,876,000. Vivo Capital LLC acquired a new position in shares of CytomX Therapeutics in the second quarter valued at approximately $13,096,000. Finally, Balyasny Asset Management L.P. bought a new position in shares of CytomX Therapeutics during the second quarter worth approximately $6,505,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Trading Down 2.4%

Shares of CytomX Therapeutics stock opened at $4.41 on Tuesday. The company has a market cap of $750.54 million, a PE ratio of -110.25 and a beta of 2.44. The company has a 50 day moving average of $5.25 and a 200-day moving average of $4.24. CytomX Therapeutics, Inc. has a 1-year low of $0.40 and a 1-year high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. Research analysts forecast that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on CTMX. Piper Sandler lifted their price target on CytomX Therapeutics from $10.00 to $12.00 and gave the stock an “overweight” rating in a report on Monday, March 23rd. Weiss Ratings downgraded CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday, March 19th. Guggenheim upped their price target on shares of CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Barclays raised their price target on shares of CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Finally, HC Wainwright boosted their price objective on shares of CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 16th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, CytomX Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.44.

Insiders Place Their Bets

In other news, CEO Sean A. Mccarthy sold 118,969 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $763,780.98. Following the completion of the transaction, the chief executive officer owned 1,078,922 shares of the company’s stock, valued at approximately $6,926,679.24. The trade was a 9.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher Ogden sold 19,323 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $124,053.66. Following the sale, the chief financial officer owned 296,948 shares of the company’s stock, valued at approximately $1,906,406.16. This represents a 6.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 191,063 shares of company stock worth $1,226,624. 6.60% of the stock is owned by company insiders.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.